Vanguard CPV-Lepto Suspensie voor injectie
Vanguard CPV-Lepto Suspensie voor injectie
Authorised
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
- Canine parvovirus, strain NL-35-D, Live
Product identification
Medicine name:
Vanguard CPV-Lepto Suspensie voor injectie
Vanguard CPV-Lepto Suspension injectable
Vanguard CPV-Lepto Injektionssuspension
Active substance:
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
- Canine parvovirus, strain NL-35-D, Live
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated40.00Hamster protective Dose 80 % (Ph. Eur. Monograph)1.00millilitre(s)
-
Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated40.00Hamster protective Dose 80 % (Ph. Eur. Monograph)1.00millilitre(s)
-
Canine parvovirus, strain NL-35-D, Live10000000.00cell culture infective dose 501.00millilitre(s)
Pharmaceutical form:
-
Suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
-
Dog
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AL04
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Belgium
Available in:
-
Belgium
Package description:
- Vanguard CPV-Lepto 25 Vials with 1 dose of Suspension for injection
- Vanguard CPV-Lepto 100 Vials with 1 dose of Suspension for injection
- Vanguard CPV-Lepto 10 Vials with 1 dose of Suspension for injection
- Vanguard CPV-Lepto 1 Vial with 1 dose of Suspension for injection
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
- Zoetis Belgium
Responsible authority:
- Federal Agency For Medicines And Health Products
Authorisation number:
- BE-V161551
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Package Leaflet
This document does not exist in this language (English). You can find it
in another language below.
How useful was this page?: